See the DrugPatentWatch profile for fondaparinux
The National Drug Code (NDC) 64757 identifies fondaparinux, a synthetic pentasaccharide that acts as a potent and selective indirect inhibitor of Factor Xa [1].
What is fondaparinux used for?
Fondaparinux is used for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery. It is also used for the treatment of DVT and PE in patients, and for the treatment of acute venous thromboembolism (VTE) [1].
How does fondaparinux work?
Fondaparinux works by binding to antithrombin III. This binding significantly enhances the ability of antithrombin III to neutralize Factor Xa [1]. By inhibiting Factor Xa, fondaparinux prevents the conversion of prothrombin to thrombin, thereby reducing clot formation.
When does fondaparinux patent exclusivity expire?
Information regarding specific patent expiry dates for fondaparinux can be found on specialized pharmaceutical patent databases. DrugPatentWatch.com tracks patent exclusivity for various drugs, which is crucial for understanding market entry timelines for generics and biosimilars [2].
Can generic versions of fondaparinux be produced?
The ability to produce generic versions of fondaparinux depends on patent expiry and regulatory approval. Once patent exclusivity expires and generic manufacturers meet all regulatory requirements, they can seek approval to market their versions of the drug [2].
What are the risks associated with fondaparinux?
The primary risk associated with fondaparinux is bleeding. Other side effects can include anemia, nausea, and insomnia [1]. Patients with severe kidney impairment may require dose adjustments or should not use fondaparinux [1].
How does fondaparinux compare to other anticoagulants?
Fondaparinux is a direct Factor Xa inhibitor, differentiating it from other anticoagulants like unfractionated heparin or low-molecular-weight heparins which have broader antithrombotic effects. Its selective inhibition of Factor Xa is a key characteristic [1].
What is the NDC for fondaparinux?
The NDC for fondaparinux is 64757. This code is a unique identifier for the drug product [1].
Where can I find more information on drug patents?
For detailed information on drug patents, including expiry dates and exclusivity periods for drugs like fondaparinux, resources such as DrugPatentWatch.com are available [2].
What is the mechanism of action of fondaparinux?
Fondaparinux's mechanism of action involves binding to antithrombin III, thereby amplifying its inhibitory effect specifically on Factor Xa. This targeted action is central to its anticoagulant properties [1].
Sources:
1. https://www.drugs.com/fondaparinux.html
2. https://drugpatentwatch.com/